Globus Medical, Inc. Class A Common Stock (GMED)

What happened? Shares of medical device company Globus Medical (NYSE:GMED) fell 11.6% in the afternoon session after the company reported third-quarter 2026 ...

Record free cash flow offset a revenue dip and a lower full-year outlook.

Medical device company Globus Medical (NYSE:GMED) missed Wall Street’s revenue expectations in Q3 2026, with sales flat year on year at $763.7 million. The c...

Medical device company Globus Medical (NYSE:GMED) fell short of the market’s revenue expectations in Q3 2026, with revenue flat year on year at $763.7 millio...

What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat...

Medical device company Globus Medical (NYSE:GMED) will be reporting results this Thursday after market close. Here’s what to expect. Globus Medical beat anal...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

Over the last six months, Globus Medical’s shares have sunk to $74.94, producing a disappointing 10.3% loss - a stark contrast to the S&P 500’s 21.4% gain. T...

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Gl...

Profitable companies tend to be more resilient, giving them the flexibility to invest and return capital to shareholders. Businesses that consistently genera...

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Globus Medical (NYSE:GMED) reported second-quarter 2026 revenue of $789.6 million, up 6% from a year earlier, as growth in its spine and trauma businesses helped offset declines in enabling technologies and Nevro sales. The company reaffirmed its full-year revenue outlook while raising its adjusted

Medical device company Globus Medical (NYSE:GMED) announced better-than-expected revenue in Q2 CY2026, with sales up 5.9% year on year to $789.6 million. The...

Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results this Thursday afternoon. Here’s what you need to know. Globus Medical b...

Globus Medical, Inspire Medical Systems, and Penumbra show varied revenue growth and analyst ratings, offering medical device investors alternatives to traditional pharmaceutical stocks.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...